Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Cytological Assessment of Donor-Site Healing After Free Gingival Grafting

8. november 2026 oppdatert av: Ayse Ege SELMAN, Biruni University

Cytological Evaluation of the Effects of Different Donor-Site Interventions on Healing After Free Gingival Graft Surgery

An adequate width of keratinized gingiva is important for maintaining periodontal and peri-implant tissue health. Free gingival grafting (FGG) is a commonly performed surgical procedure for increasing insufficient keratinized gingival width. This study aims to evaluate the effect of applying a chitosan sponge to the palatal donor site on wound healing after FGG using exfoliative cytology and to compare the findings with those obtained from a control group in which no chitosan sponge is applied.

At least 40 patients scheduled to undergo FGG because of insufficient keratinized gingival width will be included. The patients will be allocated to two groups: a test group and a control group. In the test group, a chitosan sponge will be applied to the palatal donor site, whereas no wound dressing will be applied to the palatal donor site in the control group. The primary outcome will be the keratinization index determined from cytological samples collected from the palatal donor site at one month after surgery. The keratinization index values at one month will be compared between the test and control groups.

All participants will receive detailed information about the study and the procedures, and written informed consent will be obtained. Clinical measurements will be recorded before surgery, after which the FGG procedure will be performed. Depending on group allocation, the palatal donor site will either be treated with a chitosan sponge or left without a wound dressing. Sutures will be removed on postoperative day 10.

For exfoliative cytological assessment, baseline samples will be collected from both the planned palatal donor site and the contralateral symmetrical healthy palatal site, which will not undergo surgery, in all patients. Samples collected from the symmetrical palatal site will serve as a reference for the baseline characteristics of healthy palatal mucosa. Follow-up samples will be collected exclusively from the palatal donor site on postoperative day 3,10 and at 1, 3, and 6 months. The keratinization index and other cellular features associated with wound healing will be assessed in the cytological samples. Findings obtained during the follow-up periods will be compared between the test group treated with a chitosan sponge and the control group in which no wound dressing is applied. In addition, the presence or absence of sensory loss at the palatal donor site will be evaluated using a periodontal probe.

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Antatt)

40

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 65 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Volunteering to participate in the study,
  • Being at least 18 years of age,
  • The need for SDG in patients with < 2 mm of keratinized gingiva on the vestibular side of the implant/tooth,
  • No prior surgical procedures or grafts in the palatal region,Volunteering to participate in the study,

Exclusion Criteria:

  • The presence of a systemic disease that would contraindicate surgical treatment,
  • Uncontrolled diabetes (HbA1c > 7),
  • Pregnancy or breastfeeding,
  • Autoimmune and/or inflammatory diseases of the oral cavity,
  • Active periodontal disease.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Styre

Free gingival graft surgery

Eksperimentell: Test

Free gingival graft surgery

Suturing of chitosan sponge to the palatal donor site

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Palatal donor site tissue thickness:
Tidsramme: Pre-operative

The thickness of the donor site will be measured using an endodontic reamer.

Pre-operative
Palatal donor site tissue thickness:
Tidsramme: immediate Post-operative

The thickness of the donor site will be measured using an endodontic reamer.

immediate Post-operative
Palatal donor site tissue thickness:
Tidsramme: day 10

The thickness of the donor site will be measured using an endodontic reamer.

day 10
Palatal donor site tissue thickness:
Tidsramme: day 30

The thickness of the donor site will be measured using an endodontic reamer.

day 30
Palatal donor site tissue thickness:
Tidsramme: day 90

The thickness of the donor site will be measured using an endodontic reamer.

day 90
Palatal donor site tissue thickness:
Tidsramme: day 180

The thickness of the donor site will be measured using an endodontic reamer.

day 180
Keratinization Index
Tidsramme: day 3

Cells without nuclei / Total number of cells examined (n=200) × 100

day 3
Keratinization Index
Tidsramme: day 10

Cells without nuclei / Total number of cells examined (n=200) × 100

day 10
Keratinization Index
Tidsramme: day 30

Cells without nuclei / Total number of cells examined (n=200) × 100

day 30
Keratinization Index
Tidsramme: day 90

Cells without nuclei / Total number of cells examined (n=200) × 100

day 90
Keratinization Index
Tidsramme: day 180

Cells without nuclei / Total number of cells examined (n=200) × 100

day 180
Superficial cell index
Tidsramme: day 3

Total number of cells with and without pyknotic nuclei / Total number of cells examined (n=200) × 100

day 3
Superficial cell index
Tidsramme: day 10

Total number of cells with and without pyknotic nuclei / Total number of cells examined (n=200) × 100

day 10
Superficial cell index
Tidsramme: day 30

Total number of cells with and without pyknotic nuclei / Total number of cells examined (n=200) × 100

day 30
Superficial cell index
Tidsramme: day 90

Total number of cells with and without pyknotic nuclei / Total number of cells examined (n=200) × 100

day 90
Superficial cell index
Tidsramme: day 180

Total number of cells with and without pyknotic nuclei / Total number of cells examined (n=200) × 100

day 180

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Loss of sensation
Tidsramme: Day 10

To test it objectively, two different movements will be performed with the tip of the probe: immersion and scraping.

Day 10
Loss of sensation
Tidsramme: Day 30

To test it objectively, two different movements will be performed with the tip of the probe: immersion and scraping.

Day 30
Loss of sensation
Tidsramme: Day 90

To test it objectively, two different movements will be performed with the tip of the probe: immersion and scraping.

Day 90
Loss of sensation
Tidsramme: Day 180

To test it objectively, two different movements will be performed with the tip of the probe: immersion and scraping.

Day 180

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. juli 2026

Primær fullføring (Antatt)

30. november 2026

Studiet fullført (Antatt)

30. desember 2026

Datoer for studieregistrering

Først innsendt

8. november 2026

Først innsendt som oppfylte QC-kriteriene

8. november 2026

Først lagt ut (Faktiske)

16. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

16. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

8. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • 2015-KAEK-80-23-44

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .